Humana Inc. (NYSE:HUM) Shares Sold by MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH

MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH trimmed its stake in shares of Humana Inc. (NYSE:HUM) by 78.9% in the 1st quarter, HoldingsChannel reports. The firm owned 289 shares of the insurance provider’s stock after selling 1,082 shares during the quarter. MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH’s holdings in Humana were worth $100,000 at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. Rakuten Securities Inc. acquired a new position in shares of Humana in the fourth quarter worth about $25,000. Gradient Investments LLC boosted its position in shares of Humana by 200.0% in the fourth quarter. Gradient Investments LLC now owns 60 shares of the insurance provider’s stock worth $27,000 after buying an additional 40 shares during the period. Cetera Trust Company N.A purchased a new position in shares of Humana during the fourth quarter valued at $28,000. Private Wealth Management Group LLC acquired a new position in Humana during the fourth quarter valued at $32,000. Finally, Carolinas Wealth Consulting LLC lifted its stake in Humana by 274.1% in the 4th quarter. Carolinas Wealth Consulting LLC now owns 101 shares of the insurance provider’s stock worth $46,000 after acquiring an additional 74 shares in the last quarter. Hedge funds and other institutional investors own 92.38% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on the company. Baird R W upgraded Humana to a “hold” rating in a report on Thursday, May 30th. TD Cowen decreased their target price on shares of Humana from $427.00 to $396.00 and set a “buy” rating for the company in a research note on Tuesday, April 2nd. Raymond James assumed coverage on shares of Humana in a research note on Friday, March 22nd. They issued a “market perform” rating on the stock. The Goldman Sachs Group reduced their price objective on Humana from $450.00 to $385.00 and set a “buy” rating for the company in a research report on Wednesday, April 3rd. Finally, Barclays lowered their target price on Humana from $356.00 to $310.00 and set an “equal weight” rating on the stock in a research note on Tuesday, April 2nd. Fourteen analysts have rated the stock with a hold rating and nine have given a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $409.55.

Humana Stock Performance

NYSE:HUM opened at $374.82 on Wednesday. The stock has a market capitalization of $45.17 billion, a P/E ratio of 23.34, a price-to-earnings-growth ratio of 2.16 and a beta of 0.51. Humana Inc. has a 1 year low of $298.61 and a 1 year high of $530.54. The firm has a 50 day moving average of $344.75 and a 200-day moving average of $351.38. The company has a current ratio of 1.67, a quick ratio of 1.67 and a debt-to-equity ratio of 0.77.

Humana (NYSE:HUM) last posted its quarterly earnings data on Wednesday, April 24th. The insurance provider reported $7.23 EPS for the quarter, topping analysts’ consensus estimates of $6.12 by $1.11. Humana had a return on equity of 17.76% and a net margin of 1.82%. The company had revenue of $29.61 billion for the quarter, compared to analyst estimates of $28.52 billion. During the same quarter in the previous year, the firm earned $9.38 earnings per share. The business’s revenue was up 10.7% on a year-over-year basis. As a group, sell-side analysts anticipate that Humana Inc. will post 16.27 EPS for the current fiscal year.

Humana Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, July 26th. Shareholders of record on Friday, June 28th will be issued a dividend of $0.885 per share. The ex-dividend date of this dividend is Friday, June 28th. This represents a $3.54 annualized dividend and a yield of 0.94%. Humana’s dividend payout ratio is currently 22.04%.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.